Provided by Tiger Trade Technology Pte. Ltd.

Janux Therapeutics, Inc.

15.86
-18.1300-53.34%
Post-market: 16.100.2399+1.51%17:40 EST
Volume:15.91M
Turnover:272.65M
Market Cap:953.94M
PE:-9.44
High:18.86
Open:18.51
Low:15.77
Close:33.99
52wk High:71.71
52wk Low:15.77
Shares:60.15M
Float Shares:44.97M
Volume Ratio:8.35
T/O Rate:35.39%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6802
EPS(LYR):-1.2836
ROE:-12.48%
ROA:-10.49%
PB:0.98
PE(LYR):-12.36

Loading ...

Truist Financial Keeps Their Buy Rating on Janux Therapeutics Inc (JANX)

TIPRANKS
·
Nov 10

Did Improved Q3 Results and Pipeline Progress Just Shift Janux Therapeutics' (JANX) Investment Narrative?

Simply Wall St.
·
Nov 10

Bank of America Securities Sticks to Its Buy Rating for Janux Therapeutics Inc (JANX)

TIPRANKS
·
Nov 10

Janux Therapeutics Is Maintained at Overweight by Barclays

Dow Jones
·
Nov 07

Cantor Fitzgerald Reaffirms Their Buy Rating on Janux Therapeutics Inc (JANX)

TIPRANKS
·
Nov 07

Janux Therapeutics price target raised to $48 from $47 at Barclays

TIPRANKS
·
Nov 07

Buy Rating for Janux Therapeutics: Promising Data and Strong Financial Position Highlight Growth Potential

TIPRANKS
·
Nov 07

Buy Rating on Janux Therapeutics Inc: Strong Financials and Promising Clinical Developments

TIPRANKS
·
Nov 07

Janux Therapeutics reports third quarter net loss of $24.3 million

Reuters
·
Nov 07

BRIEF-Janux Therapeutics Q3 Basic EPS USD -0.39

Reuters
·
Nov 07

Janux Therapeutics Q3 Operating Expenses USD 45.251 Million

THOMSON REUTERS
·
Nov 07

Does Analyst Optimism on Janux (JANX) Outweigh Insider Sales and Leadership Changes?

Simply Wall St.
·
Nov 03

Janux Therapeutics Inc expected to post a loss of 62 cents a share - Earnings Preview

Reuters
·
Nov 01

Janux Therapeutics Advances with Promising Study on JANX008 for Solid Tumor Treatment

TIPRANKS
·
Oct 28

Truist Financial Sticks to Their Buy Rating for Janux Therapeutics Inc (JANX)

TIPRANKS
·
Oct 20

JonesTrading Remains a Buy on Janux Therapeutics Inc (JANX)

TIPRANKS
·
Oct 17

BTIG biotech analyst holds an analyst/industry conference call

TIPRANKS
·
Oct 14

Janux Therapeutics Announces Departure of Chief Strategy Officer Byron Robinson

Reuters
·
Sep 23

Bernstein Initiates Janux Therapeutics at Overweight With $47 Price Target

MT Newswires Live
·
Sep 17

Janux Therapeutics Initiated at Overweight by Barclays

Dow Jones
·
Sep 17